Dupilumab cuts exacerbation risk in COPD patients with type 2 inflammation

Among 939 COPD patients with blood eosinophil counts ≥300/microliter and elevated exacerbation risk despite use of standard triple therapy in the phase 3 BOREAS trial, those randomized to dupilumab 300 mg SC q2wks had fewer exacerbations, better lung function and quality of life, and less severe respiratory symptoms compared with placebo recipients.